期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 64, 期 12, 页码 8474-8485出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.1c00414
关键词
-
资金
- National Institutes of Health [R35 NS116846, F31-NS110269, S10-OD021550]
- Muscular Dystrophy Association [380467]
- Myotonic US Fellowship Research grant
- National Ataxia Foundation Fellowship Research grant
This study presents druglike small molecules that bind and improve defects associated with DM2 by targeting the RNA repeat expansion. Through optimization of small molecules binding the structure adopted by r(CCGU)(exp), endogenous degradation of the aberrantly retained intron, and rescue of alternative splicing defects are achieved.
Myotonic dystrophy type 2 (DM2) is one of >40 microsatellite disorders caused by RNA repeat expansions. The DM2 repeat expansion, r(CCUG)(exp) (where exp denotes expanded repeating nucleotides), is harbored in intron 1 of the CCHC-type zinc finger nucleic acid binding protein (CNBP). The expanded RNA repeat causes disease by a gain-of-function mechanism, sequestering various RNA-binding proteins including the pre-mRNA splicing regulator MBNL1. Sequestration of MBNL1 results in its loss-of-function and concomitant deregulation of the alternative splicing of its native substrates. Notably, this r(CCUG)(exp )causes retention of intron 1 in the mature CNBP mRNA. Herein, we report druglike small molecules that bind the structure adopted by r(CCUG)(exp) and improve DM2-associated defects. These small molecules were optimized from screening hits from an RNA-focused small-molecule library to afford a compound that binds r(CCUG)(exp) specifically and with nanomolar affinity, facilitates endogenous degradation of the aberrantly retained intron in which it is harbored, and rescues alternative splicing defects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据